J. A. Verhelst, P. J. Trainer, T. A. Howlett, L. Perry, L. H. Rees, A. B. Grossman, J. A. H. Wass and G. M. Besser, “Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome,” Clinical Endocrinology, Vol. 35, 1991, pp. 169- 178.
 P. C. Myhill, S. Starkstein, T. Annus and B. B. Yeap, “Reduction in salivary cortisol concentration correlates with resolution of psychosis in Cushing’s syndrome,” Journal of Neuropsychiatry and Clinical Neuroscience, Vol. 20, 2008, pp. 113-115.
 B. E. P. Murphy, V. Dhar, A. M. Ghadirian, G. Chouinard and R. Keller, “Response to steroid suppression in major depression resistant to antidepressant therapy,” Journal of clinical Psychopharmacology, Vol. 11, No., 1991, pp. 121-126.
 Z. Rogoz, G. Skuza, J. Wójcikowski, W. A. Daniel, A. Wróbel, D. Dudek and A. Zieba, “Effect of metyrapone supplementation on imipramine therapy in patients with treatment resistant unipolar depression,” Polish Journal of Pharmacology, Vol. 56, 2004, pp. 849-255.
 J.-B. Drouet, V. Michel, A. Peinnequin, A. Alonso, N. Fidier, R. Maury, A. Buguet, R. Cespuglio and F. Canini, “Metyrapone blunts stress-induced hyperthermia and increased locomotor activity independently of glucocorticoids and neurosteroids,” Psychoneuroendocrinology, Vol. 35, No. 9, 2010, pp. 1299-1310.
 J.-B. Drouet, C. Rousset, R. Maury, V. Michel, A. Buguet, R. Cespuglio and F. Canini, “Single administration of metyrapone modifies sleep-wake patterns in the rat,” European Journal of Pharmacology, Vol. 652 No. 1-3, 2010, pp. 60-64.
 D. Rottlant, S. Ons, J. Carrasco and A. Armario, “Evidence that metyrapone can act as a stressor: effect on pituitary-adrenal hormones, plasma glucose and brain c-fos induction,” European Journal of Neuroscience, Vol. 16, 2002, pp. 693-700.
 N. Calvo, I. D. Martijena, V. A. Molina and M. Volosin, “Metyrapone pretreatment prevents the behavioral and neurochemical sequelae induced by stress,” Brain Research, Vol. 800, 1998, pp. 227-235.
 H. J. Krugers, S. Maslam, J. Korf and M. Jo?ls, “The corticosterone synthesis inhibitor metyrapone prevents hypoxia/ischemia-induced loss of synaptic function in the rat hippocampus,” Stroke, Vol. 31, 2000, pp. 1162-1172.
 V. L. Smith-Swintosky, L. C. Pettigrew, R. M. Sapolsky, C. Phares, S. D. Craddock, S. M. Brooke and M. P. Mattson, “Metyrapone, an inhibitor of glucocorticoid production, reduces brain injury induced by focal and global ischemia and seizures,” Journal of Cerebral Blood Flow and Metabolism, Vol. 16, 1996, pp. 585-598.
 O. D. Bruno, P. Metzger and W. J. Malaisse, “Inhibitory effect of metyrapone on glucose utilization by brain and muscle and on insulin release by the pancreas,” Acta Endocrinologica, Vol. 70, No. 4, 1972, pp. 710-718.
 S. M. Bl?ttner, F. Rencurel, M. R. Kaufman and U. A. Meyer, “In the regulation of cytochrome P450 genes, phenobarbital targets LKB1 for necessary activation of AMP-activated protein kinase,” Proceeding of the National Academy of Science of the United States of America, Vol. 104, No. 3, 2007, pp. 1045-1050.
 J. L. Harvey, A. J. Paine, P. Maurel and M. C. Wright, “Effect of the adrenal 11-b-hydroxylase inhibitor metyrapone on human hepatic cytochrome P-450 expression: induction of cytochrome P-450 3A4,” Drug Metabolism and Disposition, Vol. 28, No. 1, 2000, pp. 96- 101.
 C. Parthasarathy, S. Yuvaraj, R. Sivukumar, B. Ravi Sankar and K. Balasubramanian, “Metyrapone-induced corticosterone deficiency impairs glucose oxidation and steroidogenesis in Leydig cells of adult albino rats,” Endocrine Journal, Vol. 49, No. 4, 2002, pp. 405-412.
 G. Bannenberg, H.-J. Martin, I. Bélai and E. Maser, “11b-hydroxysteroid deshydrogenase type 1: tissue-specific expression and reductive metabolism of some anti-insect agent azole analogue of metyrapone,” Chemico-Biological Interactions, Vol. 143-144, 2003, pp. 449-457.
 B. Darvas, I. Bélai, A. Fónagy, P. Kulcsár and M. H. Tag El-Din, “Lethal disturbances in larval development of Neobellieria bullata caused by metyrapone derivatives,” Pesticide Science, Vol. 32, No. 2, 1991, pp. 133-139. doi:10.1002/ps.2780320202
 L. Roumen, M. P. A. Sanders, K. Pieterse, P. A. J. Hilbers, R. Plate, E. Custers, M. d. Gooyer, J. F. M. Smits, I. Beugels, J. Emmen, H. C. J. Ottenheijm, D. Leysen and J. J. R. Hermans, “Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics,” Journal of Computer Aided Molecular Design, Vol. 21, 2007, pp. 455-471.
 M. Murray, R. M. Sefton, R. Martini and A. M. Butler, “Comparative induction of CYP3A and CYP2B in rat liver by 3-benzoylpyridine and metyrapone,” Chemico- Biological Interactions, Vol. 113, 1998, pp. 161-173.
 U. F?rstermann, U. Alheid, J. C. Fr?lich and A. Mülsch, “Mechanisms of action of lipoxygenase and cytochrome P-450-mono-oxygenase inhibitors in blocking endothelium-dependent vasodilatation,” British Journal of Pharmacology, Vol. 93, 1988, pp. 569-578.
 D. J. Stuehr and M. Ikeda-Saito, “Spectral characterization of brain and macrophage nitric oxide synthases. Cytochrome P-450-like hemeproteins that contain a flavin semiquinone radical,” Journal of Biological Chemistry, Vol. 267, No. 29, 1992, pp. 20547-20550.
 A. G. Hildenbrandt, “The binding of metyrapone to cytochrome P-450 and its inhibitory action on liver microsomal mixed-function oxidase reactions,” The Proceedings of the Biochemical Society, pp. 6-7.
 R. W. Estabrook, D. Y. Cooper and O. Rosenthal, “The Light Reversible Carbon Monoxide Inhibition of the Steroid C21-Hydroxylase System of the Adrenal Cortex,” Biochem Z, Vol. 338, 1963, pp. 741-755.
 P. A. Williams, J. Cosme, D. M. Vinkovic, A. Ward, H. C. Angove, P. J. Day, C. Vonrhein, I. J. Tickle and H. Jhoti, “Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone,” Science, Vol. 305, No. 30 july, 2004, pp. 683-686.
 W. Li, H. Liu, X. Luo, W. Zhu, Y. Tang, J. R. Halpert and H. Jiang, “Possible pathway(s) of metyrapone egress from the active site of cytochrome P450 3A4: A molecular dynamics simulation,” Drug Metabolism and Disposition, Vol. 35, No. 4, 2007, pp. 689-696.
 S. Lupien, R. Richter, S. C. Risen, A. Mirow, J. C. Gillin and R. L. Hauger, “Time course of the corticosteroid- dopaminergic interaction during metyrapone and dexamethasone administration,” Psychiatry Research, Vol. 58, No. 1, 1995, pp. 23-35. doi:10.1016/0165-1781(95)02646-E
 S. Kawato, M. Yamada and T. Kimoto, “Brain neurosteroids are 4th generation neuromessengers in the brain: Cell biophysical analysis of steroid signal transduction,” Advances in Biophysics, Vol. 37, 2003, pp. 1-48. doi:10.1016/S0065-227X(03)80002-3
 F. Djeda?ni, “Etude par RMN des phénomènes d’inclusion et d’adaptation moléculaire dans les cyclodextrines naturelles et les dérivés synthétiques,” Ph.D. Thesis, Université de Paris Sud, Paris, 1991.
 J. C. Debouzy, A. Gadelle, F. Fauvelle, S. Aous, J. Y. Pailler, E. Gentilhomme, P. Perrin and F. Lhoste, “Is uranyl scavenger hexakis(3,6-anhydro) tetrakis(2A,B,D, E-O-octyl) cyclomaltohexaose (OCT) relevant with biosystems?,” Boll Chim Farm, Vol. 140, No. 1, 2001, pp. 4-8.
 B. J. Gaffney, “Pratical considerations for the calculation of order parameters for fatty acid or phospholipid spin labels in membranes,” In: R. J. Berliner, ed., Spin Labelling Theory and Applications, Academic Press, New York London, 1976, pp. 567-571.
 S. Mabrey and J. M. Sturtevant, “Investigation of phase transitions of lipids and lipid mixtures by sensitivity differential scanning calorimetry. Proceedings of the National Academy of Sciences,” Proceedings of the National Academy of Sciences, Vol. 73, No. 11, 1976, pp. 3862-3866.
 S. Follot, J. C. Debouzy, D. Crouzier, C. Enguehard-Gueiffier, A. Gueiffier, F. Nachon, B. Lefebvre and F. Fauvelle, “Physicochemical properties and membrane interactions of anti-apoptotic derivatives 2-(4-fluoro- phenyl)-3-(pyridin-4-yl)imidazo[1,2-a]pyridine depending on the hydroxyalkylamino side chain length and conformation: an NMR and ESR study,” Eur J Med Chem, Vol. 44, No. 9, 2009, pp. 3509-3518. doi:10.1016/j.ejmech.2008.12.026
 M. P. Besenicar, A. Bavdek, A. Kladnik, P. Macek and G. Anderluh, “Kinetics of cholesterol extraction from lipid membranes by methyl-[beta]-cyclodextrin-A surface plasmon resonance approach,” Biochimica et Biophysica Acta (BBA) - Biomembranes, Vol. 1778, No. 1, 2008, pp. 175-184. doi:10.1016/j.bbamem.2007.09.022
 S. Bernèche, M. Nina and B. Roux, “Molecular Dynamics Simulation of Melittin in a Dimyristoylphosphatidylcholine Bilayer Membrane,” Biophysical Journal, Vol. 75, No. 4, 1998, pp. 1603-1618. doi:10.1016/S0006-3495(98)77604-0
 J. C. Debouzy, D. Crouzier and E. Flahaut, “Hydrophobic double walled carbon nanotubes interaction with phopholipidic model membranes: 1H-, 2H-, 31P NMR and ESR study,” Environmental Toxicology and Pharmacology, Vol. 30, No. 2, 2010, pp. 147-152. doi:10.1016/j.etap.2010.05.002
 B. Cybulska, M. Herve, E. Borowski and C. M. Gary-Bobo, “Effect of the polar head structure of polyene macrolide antifungal antibiotics on the mode of permeabilization of ergosterol- and cholesterol-containing lipidic vesicles studied by 31P-NMR,” Mol Pharmacol, Vol. 29, No. 3, 1986, pp. 293-298.